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Abstract
Background: Resource-limited countries increasingly depend on quality indicators to improve outcomes within HIV
treatment programs, but indicators of program performance suitable for use at the local program level remain
underdeveloped.
Methods: Using the existing literature as a guide, we applied standard quality improvement (QI) concepts to the
continuum of HIV care from HIV diagnosis, to enrollment and retention in care, and highlighted critical service
delivery process steps to identify opportunities for performance indicator development. We then identified existing
indicators to measure program performance, citing examples used by pivotal donor agencies, and assessed their
feasibility for use in surveying local program performance. Clinical delivery steps without existing performance
measures were identified as opportunities for measure development. Using National Quality Forum (NQF) criteria as
a guide, we developed measurement concepts suitable for use at the local program level that address existing
gaps in program performance assessment.
Results: This analysis of the HIV continuum of care identified seven critical process steps providing numerous
opportunities for performance measurement. Analysis of care delivery process steps and the application of NQF
criteria identified 24 new measure concepts that are potentially useful for improving operational performance in
HIV care at the local level.
Conclusion: An evidence-based set of program-level quality indicators is critical for the improvement of HIV care in
resource-limited settings. These performance indicators should be utilized as treatment programs continue to grow.
Keywords: HIV/AIDS, Resource-poor, Quality indicator, Quality improvement
Background
HIV care in low and middle income countries
Since first reported in 1981, HIV/AIDS has claimed the
lives of nearly 27 million people worldwide [1,2]. The
United Nations Development Program named HIV
responsible for “the single greatest reversal in human
development” in modern history [3]. In response, the
international community has committed to reversing the
toll of this pandemic through financial support, political
advocacy, and civic engagement [4]. With these efforts,
6.7 million people living with HIV in low-and middle-in-
come countries now have access to lifesaving treatment,
representing a 16-fold increase in 7 years [5]. The intro-
duction of antiretroviral therapy (ART) has been esti-
mated to have averted 2.5 million deaths in those
settings [5].
This progress has been inconsistent across communi-
ties and countries. HIV remains under-diagnosed, many
patients present late to care or not at all, some do not
receive therapy despite clinical eligibility, and others do
not remain in care over time [1,6-12]. Addressing these
challenges will require provision of new services in
addition to improvement of the quality of existing ser-
vices. The latter suggests an opportunity to apply the
tools of quality improvement (QI) championed in well-
resourced nations [4,13].
Several major global HIV donor and advocacy agencies
have worked to consolidate performance indicators for
HIV programs [1]. Increasing attention has been paid to
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alignment with host-country goals. However, several
weaknesses remain. The strategic framework for moni-
toring and evaluation utilized by donor and advocacy
agencies may not always be consistent with the improve-
ment model where the focus of measurement is on
process and outcome measures, and change is implemen-
ted at the smallest replicable unit – the microsystem of
healthcare delivery. National and global indicators pro-
vide a broad picture of the scope, size, and impact of
HIV services, and are important for strategic planning
and resource allocation. Therefore, national and global
indicators should not be replaced by program-level indi-
cators. However, program-level indicators remain incom-
plete, and a carefully selected set of measures collected at
6 to 12-month intervals provide important data that can
be disseminated to staff to guide QI efforts [1].
Among the available quality indicators for HIV, several
critical points including linkage to care, ART eligibility,
and ART preparations as well as important patient
reported and clinical outcomes are either not repre-
sented, or are poorly represented. In addition, current
indicator and reporting requirements are often decentra-
lized and dependent on donor agencies [14]. In a study
of data quality from the international ART-LINC group,
67% of sites received funding from two sources, and 24%
from three [14]. In the same study, only 61% of pro-
grams used the same software for data collection and
management, creating a gap between measurement, clin-
ical care and improvement, while increasing the cost
and complexity of monitoring and evaluation [14]. This
study suggests that competing priorities from multiple
funding sources create barriers to data collection on
additional indicators that may be crucial to local im-
provement and underscores the importance of identifying
a set of measures that will meet reporting, stakeholder,
and local quality improvement needs.
The aim of this manuscript is to help care delivery
programs better utilize quality improvement methods by
providing them with a better ability to assess their own
performance. More specifically, we propose a framework
for considering performance measures based on the con-
tinuum of HIV care. We then identify where gaps exist
between available measures and those measure concepts
identified by our framework.
To accomplish this aim, we first provide an overview
of quality improvement (QI) science in healthcare, high-
lighting important QI concepts. We then summarize the
global HIV-specific QI measurement efforts in resource-
limited settings utilized by three pivotal advocacy and
donor agencies with broad international reach (UNAIDS,
the Global Fund to fight AIDS, Tuberculosis, and Malaria,
and the President’s Emergency Plan for AIDS Relief
[PEPFAR]). We describe performance along the HIV
care continuum, identifying potential foci for quality im-
provement, and gaps in current measurement efforts.
Finally, we propose a set of quality indicators for HIV
service delivery programs to address current measurement
gaps along the HIVcare continuum.
Methods
To summarize HIV QI concepts and identify existing
performance assessment measures, we conducted a li-
terature review using Medline and EMBASE databases in
addition to published reports from UNAIDS, the Global
Fund, and PEPFAR. Using available literature, we devel-
oped an HIVcare continuum framework, paying close at-
tention to key process steps and outcomes susceptible to
measurement as called for in process improvement
theory. Having identified the key process steps required
to deliver HIV services, we again searched the literature
for studies addressing performance in each of the identi-
fied process steps. We also assessed the extent to which
existing performance measures addressed process issues
identified at each of the process steps. We used the
literature to propose additional measures and assessed
the extent to which each met National Quality Forum
(NQF) recommendations for measure importance,
usability and feasibility [15]. Assessment of measurement
properties (i.e. validity, reliability, etc.) was beyond the
scope of this work.
Results
The science of quality improvement in healthcare
Borrowing from industrial quality control methods devel-
oped in the 1950’s and 1960’s, healthcare in resource-rich
countries has seen rapid growth in the understanding
and development of methods that improve quality [16].
Quality improvement relies both on a philosophy, the
pursuit of continuous performance improvement, and a
diverse armamentarium of methods. These methods
include operations research, assessment of healthcare
delivery processes, participative management, and setting
of performance benchmarks. They also include determi-
ning best practices, often codified in practice guidelines,
and measuring adherence to those best practices [17].
Central to achieving high quality of care is the defin-
ition, observation and measurement of key system indi-
cators – the fundamental metrics in quality improvement
measurement. Many healthcare QI experts support the
Donabedian model, which suggests that indicators
should assess the structures (characteristics of physical
deployment of resources such as physicians, nurses,
buildings and supplies), processes (what health profes-
sionals do with people), and outcomes of care (what hap-
pens to people, especially with regard to their health)
[18]. These attributes of a system of care are not of equal
value. Outcomes matter most, but are also the most
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indicator of healthcare quality than structural measures
because they allow assessment of timeliness and appro-
priateness of care [19]. While individual indicators may
reflect specific measures of importance, they may not in
isolation lead to an understanding of the broader land-
scape and affect change that leads to improvement. To
address this, the “balanced scorecard” approach was
designed to merge a set of measures (including struc-
tures, processes and outcomes) across several domains
(e.g., timeliness, cost-effectiveness, appropriateness) in a
format that would enable managers to translate the orga-
nization’s mission into a specific subset of measurable
objectives [20].
The development and selection of indicators is linked
to data collection, implementation of targeted activities,
and evaluation of their impact on health outcomes
[16,21]. Once identified, quality indicators should be
evaluated for their importance, scientific acceptability,
usability, and feasibility [22]. These measures can then
be used at the program level (the point of service deliv-
ery) to assess healthcare quality and identify areas for
improvement. This process is most effectively executed
at the level of the microsystem – a small group of people
who work together to provide care to patients; who best
understand the challenges to improvement; and are
responsible for implementing the changes that drive im-
provement [23]. For HIV treatment programs, such a
team may consist of clinicians (physicians, nurses, phar-
macists, aides, etc.), counselors, home-based care/out-
reach workers, and clerical/data entry staff.
HIV-specific QI measurement in resource-limited countries
The Joint United Nations Program on HIV/AIDS
(UNAIDS), along with major funding bodies, has pro-
vided guidance and leadership to improve the capacity
and quality of HIV care globally. UN member states
pledged to regularly report progress on their commit-
ment to reversing the spread of HIV/AIDS; in 2003, the
UNAIDS Secretariat developed a set of core indicators to
monitor that progress [1,13]. The largest multilateral
donor agency for the HIV response, the Global Fund to
fight AIDS, Tuberculosis and Malaria (GFATM) was
established to increase financing for these infections in
2002 [24]. The US President’s Emergency Plan for AIDS
Relief (PEPFAR), the largest bilateral funding organiza-
tion for the global HIV/AIDS pandemic, was launched by
the US Congress in 2003 [25-27].
UNAIDS, the Global Fund, and PEPFAR have adopted
an overarching framework for the monitoring and evalu-
ation of national HIV/AIDS programs in host countries.
This framework relies on a logic model that measures
inputs, activities, outputs, outcomes, and impacts, which
provide information on what goes into a program and
the results achieved [28]. The measures are indicators
collected at the program, provincial, and local levels, and
are aggregated to reflect the progress of national HIV/
AIDS programs in meeting country, donor, and advocacy
goals. They are multifunctional and provide guidance on
the strategic planning, coordination and implementation
of programmatic efforts for the global HIV/AIDS
response, accountability to donor agencies, and assess-
ments of program effectiveness [28-31].
Despite attempts to align monitoring and evaluation
efforts, the UN and others, recognizing a lack of uni-
formity in key system measures, published a set of 25
core indicators in 2007 on which all countries were to
report (Tables 1) [1]. GFATM-supported programs report
on a minimum set of 40 national indicators; 25 of these
are from the UN General Assembly requirements, and
an additional 15 indicators span antiretroviral therapy
treatment programs, development of HIV workplace
programs, and reduction of stigma (Tables 1) [28]. While
some indicators were appropriate for program-level
monitoring, many were not, and the Global Fund recog-
nized that additional program-level indicators were
needed [28].
Most recently, PEPFAR changed its monitoring and
evaluation framework, calling for increased host country
ownership, greater alignment of indicators with host
country reporting needs, and inclusion of indicators
measuring coverage and quality of services [31]. In
addition, since 2006, PEPFAR has implemented a QI ini-
tiative, HEALTHQUAL, which helps participants mea-
sure key indicators and develop QI programs to meet
improvement goals [26]. HEALTHQUAL programs are
currently utilized in several PEPFAR countries and many
of the indicators endorsed are program-level measures
defined to meet program and country needs [26,32].
The continuum of HIV care as a framework for
developing quality improvement measures
Despite improved care resulting from scale-up of the
global HIV/AIDS response, substantial morbidity and
mortality can still be traced to inadequacies in care deli-
very at distinct points along the HIV care continuum
(Figure 1). These critical points include diagnosis, linkage
to care, initiation of antiretroviral therapy, treatment or
prophylaxis of opportunistic infections, and retention in
care over time [8,33]. Successful patient outcomes are
contingent upon a high degree of success at each and
every point on this continuum [34,35]. While barriers to
optimal care are not yet fully elucidated, quality indica-
tors focused on essential points along the care con-
tinuum will be necessary to identify weaknesses and
design interventions to maximize performance. In the
descriptions below we highlight the seven key process
steps in the HIV care continuum; to: 1) summarize the
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present our assessment of the opportunities for perfor-
mance measure development.
a. HIV testing and diagnosis
The entry point to HIV treatment is through testing and
diagnosis, yet only 30% of women and 17% of men in
Sub-Saharan Africa are aware of their HIV status [4].
Historically, HIV testing has been provider-driven and
prompted by symptoms manifested in the advanced
stages of HIV disease [36]. Further, uptake of voluntary
counseling and testing (VCT) at health service sites has
been estimated at under 50% in several Sub-Saharan
African countries [37,38]. Recognizing the importance of
expanding HIV testing, the WHO recommended pro-
vider-initiated, opt-out HIV testing in 2007 [39]. In
addition to health service-based VCT, other models,
including free-standing, mobile, community-based,
Table 1 Summary of current HIV testing, treatment, and care indicators
STEP ALONG CONTINUUM INDICATORS
UNAIDS Global Fund for HIV, TB, & Malaria PEPFAR
a) HIV Testing & Diagnosis % high risk persons HIV-
tested with known result last
12 months
% high risk persons HIV-tested with
known result last 12 months
# persons HIV-tested & received
result
% M & F 15-49y HIV tested
with known result last 12
months
% M & F 15-49y HIV-tested with known
result last 12 months
% M & F 15-49y HIV-tested with
known result last 12 months
% sexually active M & F 15-24y HIV-tested
with known result last 12 months
b) Linkage to Care
c) ART Eligibility: Clinical,
Laboratory, & Psychosocial
Assessment↕
% patients with incident TB
treated for TB & HIV
% patients screened for TB
% patients that started TB
treatment
# malnourished patients that
received therapeutic or
supplementary food
# eligible clients that received
food &/or nutrition services
d) ART Preparation: Literacy
Training, OI Prophylaxis, and
Adherence Assessment↕
% eligible adults & children that received
co-trimoxazole prophylaxis
# patients that received co-
trimoxazole prophylaxis
e) ART Initiation % adults & children with
advanced HIV receiving ART
% adults & children with advanced HIV
receiving ART
% adults & children with advanced
HIV receiving ART
% ART facilities monitoring CD4 in
accordance with national guidelines
# adults and children with HIV
infection newly enrolled on ART
# and% persons starting ART who picked
up all ART drugs on time
# adults and children with
advanced HIV infection receiving
ART
% ART facilities that have experienced a
stock-out of at least one required ART
drug in the last 12 months
f) Retention in Care % adults & children known to
be on treatment 12 months
after ART initiation
% of adults & children known to
be alive & on treatment 12
months after ART initiation
Clinical Outcomes
Other % health facilities that offer ART # service outlets providing ART
services according to national or
international standards
# health workers trained to deliver
ART services according to
published standards
A-F are points on the HIV care continuum shown in Figure 1; ART: antiretroviral therapy, TB: tuberculosis; Global Fund recommended indicators, disaggregated by
sex, age, and pregnancy status; ↕reference group is HIV positive patients enrolled in HIV care.
Ahonkhai et al. BMC Health Services Research 2012, 12:427 Page 4 of 12
http://www.biomedcentral.com/1472-6963/12/427home-based, and self-testing have also been studied
[36,37,39-42]. Routine monitoring of VCT uptake may
inform the most successful models.
Quality measures for HIV/AIDS treatment programs
should first assess how the system performs with regard
to HIV testing. The current UNAIDS, PEPFAR, and
Global Fund reports contain indicators that measure
HIV testing in several sub-populations [1]. Given the
poor uptake of most VCT models to date, additional
indicators highlighting the adoption of alternative VCT
models (such as routine, healthcare-based, or home-
based) could be used to provide benchmarks for future
performance [36].
b. linkage to care
After diagnosis, HIV-infected patients must be success-
fully linked to treatment programs. There is a paucity of
data on linkage to care in resource-limited countries.
Studies in southern Africa suggest that 50-70% of
patients who tested positive for HIV enrolled in clinical
care within 3–9 months of diagnosis, representing the
largest lost opportunity to engage patients along the
HIV care continuum [6,7,43]. In one systematic review
of HIV treatment programs in Sub-Saharan Africa a
median of 59% of patients successfully link from HIV
testing to CD4 testing or clinical staging [44]. Features
such as multiple care sites (e.g. for HIV testing, CD4
count testing, and tuberculosis treatment), long wait
times for appointments and receipt of test results, in
addition to transportation barriers and medication costs
are obstacles to effective linkage [8,10,45,46]. Definitions
of linkage to care are not straightforward [44]. In some
clinical settings, patients may report to a facility outside
of a clinic for CD4 testing, and thus may obtain CD4
testing without being linked to care in an HIV treatment
program. In addition, some have argued that patients
who are not yet eligible for ART at the time of HIV diag-
nosis may need to have multiple clinical visits to demon-
strate effective linkage to care [44,46].
While the barriers to linkage to care are not fully
understood, indicators that assess delays in these steps,
such as time from diagnosis to enrollment in care can
still be defined [6,7]. Such measures are currently lack-
ing, and are challenging to programs that do not have
health system infrastructure that supports patient identi-
fication across different healthcare providers. Nonethe-
less, measures for linkage to care must identify patients
who have enrolled in HIV clinics. A recent systematic
review of retention in HIV care from testing to treat-
ment in Sub-Saharan Africa calls for standardization of
terms to facilitate the study of linkage to care across
multiple care sites. The authors define 2 stages addres-
sing care linkage. Stage 1 begins after receipt of a posi-
tive HIV test, and ends with the receipt of CD4 count or
clinical staging result and referral to ART or pre-ART
care; stage 2 begins after referral to pre-ART care, and
ends with ART eligibility [44]. Adoption of such stan-
dard definitions would be an important step in develo-
ping quality measures.
c. Antiretroviral therapy eligibility
Once enrolled in HIV care, patients should be staged
with clinical and psychosocial evaluation in addition to
CD4 count testing to assess eligibility for antiretroviral
therapy, and to screen and prophylax for opportunistic
infections [47]. Given evidence that starting treatment
earlier reduces the risk of AIDS and death, the WHO in
2009 increased the recommended threshold for ART
Figure 1 The Continuum of HIV Care in Resource Limited Settings. Points A-F represent distinct structures, processes, and outcomes along
the HIV care continuum. Triangles (Δ) represent structures, ovals ( ) represent processes, and rectangles (▭) represent outcomes. ART:
antiretroviral therapy, LTFU: lost to follow-up, VCT: Voluntary Counseling and Testing, OI: opportunistic infection.
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Nonetheless, patients in most low-income countries
present to care much later (median CD4 108 cells/uL)
than their counterparts in high-income countries
(median 234 cells/uL) [11]. This late presentation is
clearly associated with an increased risk of death [11,48].
Further, recent evidence from HPTN 052, a trial of anti-
retroviral therapy in couples with discordant HIV status,
showed significantly less transmission when antiretro-
viral therapy was initiated with a CD4 cell count of 350–
500 cells/uL compared to less than 250 cells/uL. Thus, it
is likely that antiretroviral therapy eligibility will move
even earlier in disease, and will present new challenges
to LMIC [49].
Tuberculosis (TB) is the leading cause of illness and
death among people living with HIV worldwide [50].
Screening for TB upon entry into HIV clinic, prompt
treatment for active TB, and disease prophylaxis were
recommended by the WHO as priority interventions in
2010, but uptake is poor [50]. In 2009, only 5% of the 33
million people living with HIV were screened for TB,
and optimal screening methods are yet to be established
[51-54].
Though not standard practice, increasing program-
matic support has also focused on food supplementation,
given the importance of food insecurity and malnutrition
on outcomes of HIV-infected patients [55-57]. Recent
data from resource-limited settings demonstrates that
food assistance is associated with increased body mass
index and better clinic adherence [58,59]. In addition,
one study from rural Uganda suggests that early initi-
ation of antiretroviral therapy may improve physical
health status and thereby improve food security [60].
d. Antiretroviral therapy – preparation and initiation
After disease staging, most HIV treatment programs
have incorporated a process to assess antiretroviral ther-
apy readiness that includes psychosocial assessment,
adherence counseling, and identification of a treatment
supporter. This process typically spans several clinical
visits [61-63]. Many programs describe long delays in
antiretroviral therapy initiation, with patients waiting up
to 120 days to complete adherence training [8]. Stock-
outs of essential drugs affect at least 11% of patients on
antiretroviral therapy treatment, according to one study
in Côte d’Ivoire. Resultant treatment discontinuation is
associated with increased risk of care interruption or
death [64]. Though poor adherence to antiretroviral
therapy is associated with increased mortality, the opti-
mal format and duration of antiretroviral therapy literacy
training, and its impact on adherence, have not been
established [65]. One study in Uganda found that com-
pletion of adherence training prior to ART initiation did
not improve adherence [66]. In addition to these delays,
16-45% of patients are also lost from care before starting
antiretroviral therapy, and others die while waiting to
start treatment [8,44,46,67].
Substantial delays also exist in the time from enroll-
ment in care to full clinical assessment and ART initi-
ation [6,7,61]. Potential indicators could measure the
percentage of patients enrolled in an HIV care program
that receive a CD4 count within 3 months of HIV diag-
nosis, or the delay to initiation of ART in eligible
patients. Indicators could also be defined to determine
the proportion of patients screened for concomitant TB
infection, which is a critical problem in those who are
HIV-infected.
e. Retention in care
For patients enrolled in antiretroviral therapy programs,
high program attrition rates have been described, with
15-55% of patients lost from care between 6 and
36 months [9,10,45]. In programs that have actively
traced patients lost to follow-up, up to 40% were found
to be dead [8,10,63]. Some patients transfer care to other
programs, and others cycle in and out of care with brief
interruptions but worse virologic control than those who
remain in care [68,69]. As a result, patient retention has
been increasingly recognized as an important program
indicator.
Once initiated on antiretroviral therapy, patients
should be monitored for medication adherence and
toxicity in accordance with local guidelines. These efforts
require reliable medication supply chains and laboratory
services, which can be assessed through specific indica-
tors such as the number of stock-outs of essential medi-
cations per 6-month period. These measures would
identify the greatest delays in the system, potential inter-
ventions, and appropriate targets for future performance.
f. Clinical outcomes
Optimally, HIV-infected patients will remain in care, on
antiretroviral therapy, with controlled disease. However,
patients in resource-limited settings who are initiated on
antiretroviral therapy are 3.5 times more likely to die
than patients in resource-rich countries [11]. This risk of
death is highest in the first few months after antiretro-
viral therapy initiation, and has been attributed to pres-
entation to care with advanced disease [12,70]. Despite
the increased risk of early death, patients in resource-
limited and resource-rich settings appear to gain similar
immunologic and virologic benefit from antiretroviral
therapy [71-73]. Approximately 70% of those on therapy
achieve virologic suppression at 6 months [11,72]. WHO
has provided guidelines for treatment failure based on
CD4 count response, but discordant virologic and im-
munologic responses to antiretroviral therapy may occur
in up to 20-30% of patients, and viral load monitoring is
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[47,74,75]. Patients who do fail therapy may require in-
tensive adherence interventions, or switching to more
costly second and third-line treatment regimens [76].
Improved data collection mechanisms, unique patient
identifiers, electronic medical records, use of patient
trackers, and program cost subsidies may reduce loss to
follow-up [10,14,45]. UNAIDS and PEPFAR define one
indicator that measures 12-month retention rates, but
the complementary measure, loss to follow-up is less
well defined [77]. Geng et al. suggest a sample-based
approach to estimate the outcomes of these patients,
which may be appropriate to help programs understand
barriers to retention [78]. In addition to patients
initiated on antiretroviral therapy, it is important to
monitor patients who are antiretroviral therapy ineligible
at the time of enrollment, to ensure that they are not
lost to follow-up despite earlier presentation to care. An
indicator measuring the percentage of patients antiretro-
viral therapy ineligible at baseline who receive a follow-
up CD4 count in 6 months could capture this.
An indicator scorecard for HIV programs in resource-
limited settings should ultimately contain metrics
reflecting clinical and patient-reported outcomes. These
should be important measures in their own right, or
have known association with clinical outcomes, such as
retention in care, mortality (both before and after anti-
retroviral therapy initiation), as well as treatment failure
and switches to second-line therapy.
g. Patient-reported outcomes: health-related quality of life
and patient satisfaction
The Institute of Medicine defines patient-centered care
(care that is respectful and responsive to individuals) as
one of the six aims for improving the delivery of quality
health care [79]. Patient-reported outcomes such as
quality of life and service satisfaction are examples of
measures that characterize patient-centered care [80].
Health related quality of life (HR-QOL) has been
increasingly recognized as an important outcome, par-
ticularly as HIV has transformed into a chronic disease
in the effective ART era [81,82]. HR-QOL is a complex
measure that includes several dimensions including
physical function, symptoms, performance of social
roles, emotional status, cognitive functioning, and indi-
vidual feelings about health [80,83,84]. Several HR-QOL
scales have been developed for use across international
settings (WHO-QOL, PRO-QOL) and for HIV research
in research-rich settings (MOS-HIV, FAHI, HOPES,
HAT QOL, AIDS-HAQ, MQOL-HIV) [83-90]. Most of
these instruments were developed in the pre-ART or
pre-effective ART era, are long, and were developed for
research rather than routine clinical practice. There is
no consensus on the optimal tool for measuring HR-
QOL among patients infected with HIV [81].
Several studies have described a range of challenges for
poor patients seeking medical care in resource-limited
settings and across the globe, such as difficulty accessing
care, high direct and indirect costs of care, long wait
times, and poor treatment by staff [10,45,78,91-94].
These challenges can all influence patient satisfaction,
defined as the extent to which a patient’s health care
experience matches his or her expectations [95]. There
has been relatively little focus on patient satisfaction with
HIV care services in resource-limited settings [96-101].
More effort is needed to identify and standardize
metrics for quality of life and care satisfaction that can
be used in routine clinical practice in resource-limited
settings [84]. The AIDS Clinical Trials Group (ACTG)
has used a brief 2-question measure (one 5-point likert
scale, and another rating on a scale of 1–100) to evaluate
patient reported health status in the ACTG Longitudinal
Linked Randomized Trials protocol [102]. Health status
measures a dimension of quality of life that is impacted
by health care satisfaction [83-85]. These ACTG mea-
sures may provide a useful starting point for the
assessment of important patient reported-outcomes to
promote patient-centered care. Because of the con-
straints posed by limited resources, it becomes even
more critical to focus on indicators that will have the
greatest impact on each health system and the patients it
serves [14].
Proposed quality measures for HIV programs in resource-
limited countries
The set of quality indicators currently used to assess the
treatment and care of HIV programs in resource-limited
countries lacks focus on several areas most likely to
improve HIV outcomes (Table 1) [11,77,103]. The ten-
sion between funder needs for accountability and stra-
tegic planning, and evaluation and program needs for
local improvement, may be difficult to harmonize with a
single set of indicators. Therefore, using the model in
Figure 1 as a framework, we assessed the literature
describing the operational challenges facing HIV care in
resource-poor settings. Utilization of this framework,
along with the selection of indicators measuring both
processes of care and key clinical and patient reported
outcomes guided the development of a set of 24
program-level measure concepts to guide improvement
for HIV treatment programs (Table 2). The measure
concepts were designed to address the limitations of
current indicators described above, as well as Utilization
of this framework, along with Utilization of this frame-
work, along with the NQF criteria of importance, usabi-
lity, and feasibility.
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process measures to illustrate where patients who suc-
cessfully present to clinic receive their testing (clinic-
based vs. home or mobile testing), and to inform whether
partners of known HIV-infected patients are receiving
testing. These data will allow HIV treatment programs to
provide critical feedback about which local HIV testing
modalities are most successful and may benefit from
scale-up, in addition to which are least successful and
could benefit from improvement efforts.
To determine program performance around linkage to
HIV care, we recommend five process measures measur-
ing both stage 1 (from receipt of a positive HIV test to
receipt of CD4 count or clinical staging result and refer-
ral to ART or pre-ARTcare) and stage 2 (from referral to
pre-ART care to ART eligibility) linkage as defined by
Rosen et al., [44]. The most effective measurements of
linkage to care require the merging of data from HIV
testing and treatment centers, which are rarely available
in resource-limited settings [44,46]. Our proposed mea-
sures can be captured at the point of HIV care alone.
We propose six process and one outcome measure to
assess program performance on it’s efficiency in deter-
mining ART eligibility and effectively initiating patients
on ART. These include screening for opportunistic infec-
tions and nutritional needs in addition to ensuring
adequate drug supply, measuring the time it takes to
identify and initiate ART-eligible patients on life-saving
therapy, and concordance with local ART monitoring
guidelines. The proposed outcome measure provides
Table 2 Proposed scorecard of program-level quality measures
STEP ALONG CONTINUUM MEASURE
a) HIV Testing and Diagnosis ▪% of patients diagnosed on site [P]
▪% of patients diagnosed in other medical facilities [P]
▪% of patients diagnosed via home-based test [P]
▪% of patients diagnosed in mobile testing unit [P]
▪% of couples whose partners have been HIV tested and are aware of results [P]
b) Linkage to Care ▪ Median days from HIV diagnosis to referral for ART or pre-ART care [P]
▪% of patients ART ineligible at baseline who receive a follow-up CD4 count in
6 months [P]
▪ Median days from clinic enrollment to ART eligibility [P]
▪% of patients who are enrolled in HIV clinic, received CD4 count & results within
3 months of HIV diagnosis [P]
▪% of patients with CD4 count≤200 cells/uL, &≤350 cells/uL at presentation [P]
c) ART Eligibility: Clinical, Laboratory & Psychosocial
Assessment
▪% of patients screened for tuberculosis [P]
▪% of eligible patients provided with nutritional supplementation [P]
▪% of ART-eligible patients who died before ART initiation [O]
d) ART Preparation: Literacy Training, OI Prophylaxis,
and Adherence Assessment
▪ Median days from enrollment to ART initiation for eligible patients [P]
▪ Median days from enrollment to completion of ART literacy training for eligible
patients [P]
e) ART Initiation ▪ # drug stock outs in last quarter for first-line ART drugs or cotrimoxazole [P]
▪ Local guideline concordance (e.g. CD4 testing, adherence monitoring, assessment for
drug toxicity, OI screening & prophylaxis) [P]
f) Retention in Care ▪% of patients retained in care 6 and 12 months from enrollment (ART eligible and ART-
ineligible) [O]
▪% of patients who transferred care to other clinics 6 and 12 months from enrollment
[O]
▪% of patients deemed lost to follow-up who have been contacted by clinic staff to
determine outcome [O]
g) Clinical Outcomes ▪% of patients on ART with undetectable viral load at 12 months [O]
▪% of patients on ART requiring switch to second-line therapy for treatment failure at 12
and 24 months [O]
▪% of patients (ART-eligible on and off ART) who died 12 months after enrollment [O]
h) Patient Reported Outcomes ▪ patient-reported health status 6 and 12 months after clinic enrollment [O]
[P] = process measure, [O] = outcome measure.
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deaths of ART-eligible patients who die before starting
therapy.
Finally, we outline five outcome and one process meas-
ure addressing retention in care, patient health status,
and important clinical outcomes (virologic suppression,
use of second-line therapy, and mortality). Our measures
of care retention, in addition to assessing this as an
outcome, also necessitate that HIV care delivery pro-
grams ask whether they have intervened to decrease
LTFU and improve retention. This set of measures
encompasses data on endpoints important to patients,
clinicians, and administrators.
Discussion
Our proposed measurement framework and set of pro-
gram-level quality indicators have several strengths. The
HIV care continuum is an increasingly utilized paradigm
for implementation practice and research in HIV service
delivery, and thus anchors quality measurement around
a familiar construct for service providers. Building our
framework around the HIV care continuum also allows
us to take advantage of implementation research identi-
fying weaknesses in the care continuum, and potential
areas for quality improvement. Our identification of
measures reflecting processes and outcomes of care
moves away from volumetric endpoints that highlight
quantity rather than quality of services. Finally,
standardization of a set a quality measures allows for
comparison of performance across programs, enabling
the formulation of benchmarks for appropriate care and
identifying best practices in care delivery.
Taken in combination, the proposed measures form
the basis of a balanced scorecard of crucial, evidence-
based objectives for successful HIV service delivery pro-
grams in resource-limited settings. The proposed meas-
ure concepts will require further specification and
standardization before they can be implemented as indi-
cators (as described above). As is the case in the devel-
opment of performance measures, some will prove more
useful than others; this is difficult to predict prior to
implementation. Because program strengths and weak-
nesses differ from site to site, some programs will find
certain measures more useful than others.
These proposed measures also have limitations. The
NQF suggests that quality measures meet 4 criteria: im-
portance, usability, feasibility, and scientific acceptability.
While we considered the NQF’s criteria for performance
measures (importance, usability, and feasibility), in ma-
king recommendations, the latter two components can
only be fully appreciated once measures are specified
and field-tested. Usability and feasibility will invariably
depend upon the data collection systems available at the
program level. An assessment of scientific acceptability
(reliability and validity) of the proposed measures will
also be important. Finally, measurement alone will not
improve the quality of patient care without being linked
explicitly to the dissemination of data to care teams, and
empowering these teams to adapt care processes to
improve performance and the quality of care provided.
Building this type of approach to quality improvement
into organizations in well-resourced countries has proved
challenging, so there will undoubtedly be challenges in
resource-limited settings as well.
Conclusions
An aphorism in quality improvement science ascribed to
one of its founders, William Deming, states; “Every sys-
tem is perfectly designed to achieve exactly the results it
gets.” With the rapid scale-up of life-saving therapy for
HIV/AIDS, it is important to consider the quality
challenges in the system that has emerged for this care
in resource-limited settings. The challenges are high-
lighted by inadequate HIV testing and late presentation
to care, poor linkage, major delays in ART initiation,
and high loss to follow-up rates, all of which limit the
life-saving gains that the system aims to promote. To
improve the quality of care provided, identification and
measurement of a quality indicator scorecard that
reflects important processes and outcomes along the
continuum of HIV care is critical. There is now substan-
tial global commitment to improving the quality of HIV
care in resource-limited settings. Focused efforts to
define and improve upon the most important quality
indicators for HIV-infected individuals are crucial as
programs continue to grow.
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